Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening healthcare budgets across the EU5 mean payers must make economical reimbursement decisions, and hematologist-oncologists must work carefully within prescribing constraints arising from evolving cost-containment measures. Access & Reimbursement EU5 content examines the market access factors that influence the success of NHL therapies in the EU5 markets. The series is based on primary research with EU5 hematologist-oncologists, as well as country-specific payers. This research explores how payers and physicians interact and how reimbursement dynamics and payer policies influence the prescribing and uptake of specific therapies for chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantel cell leukemia (MCL), and diffuse large B-cell leukemia (DLBCL) at the brand level, focusing particularly on the fast-moving treatment paradigm for CLL.


Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-y...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030: Diagn...

View Details